Printed From BioPortfolio.com

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

06:18 EST 7 Dec 2017 | PMLIVE

Results will be used to pursue a first-line indication in NSCLC

Original Article: Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Related Companies
Related Events
Related Clinical Trials
Related PubMed Entries
Related Medications

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

More From BioPortfolio on "Data backs up Roche’s Tecentriq/Avastin combo in lung cancer"

Relevant Topic

News Quicklinks